Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovery and development of epigenetic biomarkers - Issued a proprietary laboratory code by the American Medical Association's Current Procedural Terminology Editorial Board. The code was issued for the EpiSwitch Checkpoint-inhibitor Response Test, a test which predicts a patient's likely response to immune checkpoint inhibitor therapy.
"Assignment of this unique code is a critical step in the reimbursement process. This code will be effective on October 1 for all requests for insurance reimbursement, whether from Medicare, Medicaid or private payors," said Chief Operating Officer Thomas Guiel.
Current stock price: 13.94 pence, up 2.1% on Tuesday in London
12-month change: down 75%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Oxford Biodyn (OBD)